These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 9295983)

  • 1. [Severe local cutaneous necrosis during treatment with interferon-alpha and ribavirin for chronic viral hepatitis C].
    de Ledinghen V; Brudieux E; Beylot-Barry M; Belleannee G; Doutre MS; Couzigou P
    Gastroenterol Clin Biol; 1997; 21(6-7):523-4. PubMed ID: 9295983
    [No Abstract]   [Full Text] [Related]  

  • 2. Rosacea fulminans associated with pegylated interferon alpha-2B and ribavirin therapy.
    Jensen SL; Holmes R
    J Drugs Dermatol; 2003 Oct; 2(5):554-6. PubMed ID: 14558405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lingual hyperpigmentation with pegylated interferon and ribavirin therapy in patients with chronic hepatitis C.
    Sood A; Midha V; Bansal M; Goyal A; Sharma N
    Indian J Gastroenterol; 2006; 25(6):324. PubMed ID: 17264447
    [No Abstract]   [Full Text] [Related]  

  • 4. Diffuse hypertrichosis in the course of hepatitis C treatment by IFN-alpha and ribavirin.
    Misery L
    J Interferon Cytokine Res; 2002 Aug; 22(8):881-2. PubMed ID: 12396727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Ischemic anterior optic neuropathy complicating interferon alpha-2a and ribavirin treatment for acute hepatitis C].
    Yaghi C; Baz P; Koussa S; Daniel F; Haddad F; Sayegh R
    Gastroenterol Clin Biol; 2005 May; 29(5):616-7. PubMed ID: 15980766
    [No Abstract]   [Full Text] [Related]  

  • 6. [Use of anxiolytics and antidepressants before and after treatment with interferon-alpha and ribavirin in patients with hepatitis C].
    García-Toro M; Vilella Martorell A; Carral Martínez M; Jimeno Beltrán T; Román Ruiz del Moral Y; Pradas Guerrero C; Gili Planas M; Roca Bennasar M
    Gastroenterol Hepatol; 2011 Apr; 34(4):307-8. PubMed ID: 21376422
    [No Abstract]   [Full Text] [Related]  

  • 7. Psychotic mania induced by the withdrawal of pegylated interferon and ribavirin treatment.
    Ganeshalingam Y; Suleman S; Francis M
    Br J Hosp Med (Lond); 2009 Apr; 70(4):233. PubMed ID: 19357605
    [No Abstract]   [Full Text] [Related]  

  • 8. Sarcoidosis presenting as tattoo changes in a patient undergoing treatment with interferon-alpha and ribavirin.
    Werchniak AE; Cheng SX; Dhar AD; Klaus SN
    Clin Exp Dermatol; 2004 Sep; 29(5):547-8. PubMed ID: 15347347
    [No Abstract]   [Full Text] [Related]  

  • 9. New combination treatment for hepatitis C is more beneficial than standard therapy, study says.
    Levenson D
    Rep Med Guidel Outcomes Res; 2002 Oct; 13(20):5-6. PubMed ID: 12599388
    [No Abstract]   [Full Text] [Related]  

  • 10. [Probable cutaneous sarcoidosis associated with combined ribavirin and interferon-alpha therapy for chronic hepatitis C].
    Savoye G; Goria O; Herve S; Riachi G; Noblesse I; Bastien L; Courville P; Lerebours E
    Gastroenterol Clin Biol; 2000; 24(6-7):679. PubMed ID: 10962394
    [No Abstract]   [Full Text] [Related]  

  • 11. Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C.
    Li Z; Zhang Y; An J; Feng Y; Deng H; Xiao S; Ji F
    J Clin Virol; 2014 Jul; 60(3):190-5. PubMed ID: 24830933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial comment: erythropoietin for treatment-related anemia in persons with hepatitis C--questions remain.
    Yachimski P; Chung RT
    AIDS Read; 2004 Oct; 14(10):568-9. PubMed ID: 15510393
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV.
    Hoffman RG; Cohen MA; Alfonso CA; Weiss JJ; Jones S; Keller M; Condemarín JR; Chiu NM; Jacobson JM
    Psychosomatics; 2003; 44(5):417-20. PubMed ID: 12954918
    [No Abstract]   [Full Text] [Related]  

  • 14. Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C.
    Hoffmann RM; Berg T; Teuber G; Prümmer O; Leifeld L; Jung MC; Spengler U; Zeuzem S; Hopf U; Pape GR
    Z Gastroenterol; 1999 Aug; 37(8):715-23. PubMed ID: 10494606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection.
    Lafeuillade A; Hittinger G; Chadapaud S
    Lancet; 2001 Jan; 357(9252):280-1. PubMed ID: 11214134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Side effects. Bone problems may occur with hepatitis treatment.
    TreatmentUpdate; 2000 Sep; 12(6):7-8. PubMed ID: 12132465
    [No Abstract]   [Full Text] [Related]  

  • 17. Face skin hyperpigmentation during pegylated interferon and ribavirin therapy.
    Yaşar B; Yaşar Ş; Güneş P
    Turk J Gastroenterol; 2015 Mar; 26(2):189-90. PubMed ID: 25835121
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of Myasthenia gravis due to treatment of chronic hepatitis C with a combination of interferon-alpha and ribavirin.
    Bektas M; Bektas H; Gören D; Altan M; Cetinkaya H
    Digestion; 2007; 75(4):208-9. PubMed ID: 17934275
    [No Abstract]   [Full Text] [Related]  

  • 19. Psychiatric aspects of hepatitis C treatment.
    Vrbanac DB; Buljan D; Sindik I; Gelo J; Sakoman LN
    Acta Clin Croat; 2013 Sep; 52(3):346-52. PubMed ID: 24558767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
    McHutchison JG; Gordon SC; Schiff ER; Shiffman ML; Lee WM; Rustgi VK; Goodman ZD; Ling MH; Cort S; Albrecht JK
    N Engl J Med; 1998 Nov; 339(21):1485-92. PubMed ID: 9819446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.